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A B S T R A C T
Purpose
Wilms tumor (WT) is the most common pediatric renal tumor. Treatment planning under In-
ternational Society of Paediatric Oncology (SIOP) protocols is based on staging and histologic
assessment of response to preoperative chemotherapy. Despite high overall survival (OS), many
relapses occur in patients without speciﬁc risk factors, and many successfully treated patients are
exposed to treatments with signiﬁcant risks of late effects. To investigate whether molecular
biomarkers could improve risk stratiﬁcation, we assessed 1q status and other potential copy number
biomarkers in a large WT series.
Materials and Methods
WT nephrectomy samples from 586 SIOP WT 2001 patients were analyzed using a multiplex
ligation-dependent probe ampliﬁcation (MLPA) assay that measured the copy number of 1q and
other regions of interest.
Results
One hundred sixty-seven (28%) of 586 WTs had 1q gain. Five-year event-free survival (EFS) was
75.0% in patients with 1q gain (95% CI, 68.5% to 82.0%) and 88.2% in patients without gain (95%
CI, 85.0% to 91.4%). OS was 88.4% with gain (95% CI, 83.5% to 93.6%) and 94.4% without gain
(95%CI, 92.1% to 96.7%). In univariable analysis, 1q gainwas associatedwith poorer EFS (P, .001;
hazard ratio, 2.33) and OS (P = .01; hazard ratio, 2.16). The association of 1q gain with poorer EFS
retained signiﬁcance in multivariable analysis adjusted for 1p and 16q loss, sex, stage, age, and
histologic risk group. Gain of 1q remained associated with poorer EFS in tumor subsets limited to
either intermediate-risk localized disease or nonanaplastic localized disease. Other notable aber-
rations associated with poorer EFS included MYCN gain and TP53 loss.
Conclusion
Gain of 1q is a potentially valuable prognostic biomarker in WT, in addition to histologic response to
preoperative chemotherapy and tumor stage.
J Clin Oncol 34. © 2016 by American Society of Clinical Oncology. Licensed under the Creative
Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
INTRODUCTION
Wilms tumor (WT) is themost common childhood
renal malignancy.1 Most patients are treated effec-
tively, with approximately 90% achieving 5-year
survival, but new approaches are needed to improve
the outcome of the remainder, especially in cases
of recurrence, where only approximately 50% will
survive.2,3 More speciﬁc biomarkers for treatment
stratiﬁcation could also reduce the therapeutic bur-
den on the successfully treated majority. Treatment
planning is currently determined by clinical staging
and histopathologic criteria. In countries that follow
the protocols of the International Society of Paediatric
Oncology (SIOP), patients with WT typically receive
© 2016 by American Society of Clinical Oncology 1
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neoadjuvant chemotherapy, and the histopathology at nephrectomy is
used to classify patients into risk groups. Tumors with diffuse anaplasia
or that contain a high proportion of chemoresistant blastema (blastemal
type) are regarded as high risk; epithelial, stromal, mixed, and regressive
subtypes are classed as intermediate risk, and completely necrotic tu-
mors are classed as low risk.4 Using this classiﬁcation, the SIOP WT
2001 trial recently reported that doxorubicin can be safely omitted from
the treatment of stage II to III intermediate-risk histology tumors,
although it still adds beneﬁt when patients have high-risk histology.5,6
However, high-risk tumors are relatively uncommon, and most
relapses still occur in patients with localized (stage I to III) low- and
intermediate-risk histology tumors. Therefore, there is a clinical need
to improve the sensitivity and speciﬁcity of risk prediction in WT.
The SIOP WT 2001 trial included, as a secondary aim, investigation
of the potential value of including molecular biomarkers in addition
to the current use of tumor stage and histology in risk stratiﬁcation.
Previous analyses have identiﬁed multiple recurrent aberra-
tions in WT. Notable genes with documented mutations include
WT1,7-9 CTNNB1,10 WTX (AMER1),11 TP53,12 FBXW7,13 MYCN,
SIX1/2, DICER1, DROSHA, and DGCR8.14-18 Copy neutral loss of
heterozygosity on 11p, common in stromal-type tumors, can lead
to both second hit inactivation of mutated WT1 on 11p13 and
aberrant expression of the imprinted genes H19 and IGF2 on
11p15; the latter locus is also frequently targeted by epigenetic
abnormalities.19 Several WT genes, including WT1, WTX, TP53,
FBXW7, and MYCN are also subject to recurrent copy number
aberrations, as are a number of larger-scale genomic regions, but
few of these are of known prognostic relevance. Simultaneous allele
loss of 1p and 16q is associated with adverse outcome in patients
with favorable-histologyWT treated with immediate nephrectomy,
and this biomarker is already used in treatment stratiﬁcation by the
Children’s Oncology Group of North America.20 We have recently
shown thatTP53mutation and 17p loss, aberrations largely conﬁned
to anaplastic histology WT, are potential adverse indicators within
this subtype.21 However, the utility of both these biomarkers is
limited by their relative rarity. Genomic gain of 1q, one of the most
common copy number changes in WT,22-25 seems to be associated
with poor outcome, as is gain of MYCN.18 Recent studies in the
United States and United Kingdom have focused on the signiﬁcance
of 1q gain and support its prognostic value.26,27
The principal aim of this study was to assess the feasibility of
using 1q gain as a prognostic biomarker by determining its as-
sociation with event-free survival (EFS) and overall survival (OS)
in a cohort drawn entirely from the SIOP WT 2001 clinical trial
(which is, to our knowledge, the largest SIOP cohort so far ana-
lyzed for this biomarker). Accordingly, a rapid and relatively low-
cost multiplex ligation-dependent probe ampliﬁcation (MLPA)
assay28 was developed and optimized to assess the copy number
status of 1q and other key regions or gene-speciﬁc loci, including
1p, 16q, WT1, WTX, TP53, MYCN, and FBXW7.
MATERIALS AND METHODS
Patients
Patients registered prospectively in the SIOP WT 2001 clinical trial and
treatedwith preoperative chemotherapy according to standardized risk-stratiﬁed
regimens on the basis of tumor stage, histology, and metastatic response to
preoperative chemotherapy5,29 with stage I to IVWTand available frozen tumor
were eligible for this study. Selection criteria and patient characteristics are
provided in the Data Supplement (Methods). Informed consent was ob-
tained from all families. Our research was approved by local ethics com-
mittees and conducted in accordance with the Helsinki Declaration.
Samples
All samples were freshly frozen specimens obtained at nephrectomy.
Genomic DNAwas prepared by standard methods. Only WTwith a tumor
content$ 50% as determined by a pediatric pathologist were used for this
study (N = 586; Data Supplement Table S1). Full details, including sample
inclusion criteria and DNA quality control (QC) metrics, are listed in the
Data Supplement.
MLPA
The MLPA assay (P380-X2) was designed and developed in collabo-
ration with MRC-Holland (Amsterdam, the Netherlands). The panel in-
cluded 33 probes for regions or genes of interest, including seven on 1p, ﬁve
on 1q, six on 16q, and three each targetingMYCN (2p), TP53 (17p), FBXW7
(4q),WT1 (11p), andWTX (AMER1, Xq), as well as reference and QC probes
(Data Supplement Table S2). MLPA reactions were performed according to the
manufacturer’s instructions, with appropriate internal quality and external
normal controls. Polymerase chain reaction products were analyzed on an
ABI 3730 DNA Analyzer, (Thermo Fisher Scientiﬁc, Waltham, MA).
Data Analysis
Copy number ratios relative to the normal reference were calculated
with Coffalyser.NET software (MRC-Holland) using the default settings. A
numerical gain was scored when the ratios exceeded 1.2 and a loss when the
ratios were lower than 0.8; all other values were considered to be normal
diploid. For individual genes, aberrations were scored by the median ratio of
the gene-speciﬁc probes. For 1p, 1q, and 16q, a gain or loss of at least two
consecutive probed loci was required to score a chromosome arm aberration.
Associations between copy number aberrations and histopathologic sub-
types (Fig 1) were calculated by logistic regression, and survival analyses
(Table 1; Fig 2; Data Supplement) were performed using the Kaplan-Meier
estimator, log-rank test, and Cox proportional hazards regression model
(Data Supplement Methods). For multivariable analyses, the factors con-
sidered are listed in the “Variable” column of Table 2.
RESULTS
Sample Series and Histologic Subtypes
A total of 586 patients with stages I to IVWTs, in which tumor
content was conﬁrmed by histologic review, high-quality DNAwas
successfully extracted, and data exceeded QC thresholds (Data
Supplement Methods), were included in the analysis. In this
series (Data Supplement Table S1), median clinical follow-up was
68months, 92 patients had an event (relapse), and 41 patients died.
In 55% of tumors (321 of 586), at least one of the major copy
number aberrations targeted by the assay (1q gain, 1p loss, 16q loss,
MYCN gain, TP53 loss, WT1 loss, WTX loss, or FBXW7 loss) was
detected (Data Supplement Table S1). Overall, the numbers of
alterations identiﬁed across all markers were consistent with
previous reports. Some aberrations were more common in speciﬁc
subtypes (Fig 1; Data Supplement Table S3) and some signiﬁcant
associations were noted. Compared with mixed-type histology,
diffuse anaplasia was signiﬁcantly associated with TP53 (17p) loss
(P , .001), MYCN (2p) gain (P , .001), 16q loss (P , .001), and
FBXW7 (4q) loss (P , .001), the latter presumably reﬂecting an
2 © 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Chagtai et al
128.41.35.62
Information downloaded from jco.ascopubs.org and provided by at UCL Library Services on August 15, 2016 from
Copyright © 2016 American Society of Clinical Oncology. All rights reserved.
association between anaplasia andwhole-arm 4q loss, whichwe have
described previously.30 The stromal subtype was associated with
WT1 (11p) loss (P = .0014), consistent with previous reports, and
with a signiﬁcantly lower frequency of 1q gain than the other
subtypes (P = .00912). A gain of 1q was most frequent in blastemal-
type tumors (Fig 1), but not to a statistically signiﬁcant extent. We
Table 1. Univariable Survival Analyses
Patient Series Aberration No. of Patients No. of Relapses Event P Event HR 5-Year EFS No. of Deaths Death P Death HR 5-Year OS
Unselected patients 1q gain 167 43 , .001 2.33 75 19 .01 2.16 88.4
(N = 586) 1q other 419 49 88.2 22 94.4
1p loss 49 11 .17 1.55 77.9 5 .38 1.52 89
1p other 537 81 85 36 93
16q loss 94 20 .12 1.48 78.5 11 .07 1.88 89.1
16q other 492 72 85.5 30 93.3
1p and 16q loss 16 3 .76 1.22 81.2 0 .27 0.01 100
1p and 16q other 570 89 84.5 41 92.4
TP53 (17p) loss 44 19 , .001 4.03 55.2 16 , .001 9.80 63.7
TP53 (17p) other 542 73 86.7 25 94.9
WT1 (11p) loss 50 6 .45 0.73 86.6 1 .15 0.26 97.8
WT1 (11p) other 536 86 84.2 40 92.2
WTX (Xq) loss 93 10 .13 0.61 91.4 2 .04 0.26 97.8
WTX (Xq) other 493 82 83 39 91.6
MYCN (2p) gain 88 26 , .001 2.45 71.2 14 , .001 3.09 83.7
MYCN (2p) other 498 66 86.7 27 94.2
MYCN (only) gain 60 20 , .001 2.72 67.9 12 , .001 3.91 79.4
MYCN (only) other 526 72 86.3 29 94.2
FBXW7 (4q) loss 24 15 , .001 6.58 38 10 , .001 9.62 59.3
FBXW7 (4q) other 562 77 86.4 31 94
IR stage I-III 1q gain 114 22 .004 2.21 82.2 3 .99 1.01 98
(n = 441) 1q other 327 29 91.3 8 97.3
1p loss 34 6 .27 1.61 83.7 1 .88 1.17 97
1p other 407 45 89.4 10 97.5
16q loss 59 9 .4 1.36 84.6 3 .21 2.27 96.4
16q other 382 42 89.5 8 97.6
1p and 16q loss 13 2 .69 1.33 84.6 0 .56 0.01 100
1p and 16q other 428 49 89 11 97.4
TP53 (17p) loss 19 6 .004 3.23 67.4 3 , .001 8.33 88.2
TP53 (17p) other 422 45 89.9 8 97.8
WT1 (11p) loss 42 5 .94 1.03 86.3 0 .29 0.00 100
WT1 (11p) other 399 46 89.2 11 97.2
WTX (Xq) loss 79 8 .58 0.81 92.4 0 .11 0.00 100
WTX (Xq) other 362 43 88.1 11 96.9
MYCN (2p) gain 61 14 .003 2.49 78.2 4 .03 3.50 93.4
MYCN (2p) other 380 37 90.7 7 98.1
MYCN (only) gain 42 11 .001 2.86 75.7 4 .002 5.49 90.3
MYCN (only) other 399 40 90.3 7 98.2
FBXW7 (4q) loss 13 6 , .001 4.85 59.3 1 .23 3.25 100
FBXW7 (4q) other 428 45 89.9 10 97.4
Non-AH stage I-III 1q gain 131 26 .001 2.34 81.4 6 .1 2.48 95.7
(n = 482) 1q other 351 30 91.4 6 98.1
1p loss 42 8 .13 1.78 82 3 .05 3.47 92.3
1p other 440 48 89.3 9 97.9
16q loss 64 9 .59 1.22 85.7 2 .8 1.22 98.4
16q other 418 47 89 10 97.2
1p and 16q loss 14 2 .76 1.25 85.7 0 .55 0.01 100
1p and 16q other 468 54 88.7 12 97.3
TP53 (17p) loss 17 5 .02 2.82 69.3 2 .02 5.24 93.3
TP53 (17p) other 465 51 89.3 10 97.5
WT1 (11p) loss 45 5 .9 0.94 87.4 0 .27 0.00 100
WT1 (11p) other 437 51 88.7 12 97.1
WTX (Xq) loss 81 8 .5 0.77 92.6 0 .1 0.00 100
WTX (Xq) other 401 48 87.7 12 96.8
MYCN (2p) gain 63 14 .01 2.30 78.9 4 .04 3.23 93.4
MYCN (2p) other 419 42 90.1 8 98
MYCN (only) gain 43 11 .002 2.68 76.2 4 .003 5.10 90.3
MYCN (only) other 439 45 89.8 8 98.1
FBXW7 (4q) loss 13 6 , .001 4.83 59.3 1 .23 3.28 100
FBXW7 (4q) other 469 50 89.5 11 97.3
Abbreviations: AH, anaplastic histology; EFS, event-free survival; HR, hazard ratio; IR, intermediate risk; OS, overall survival.
www.jco.org © 2016 by American Society of Clinical Oncology 3
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also noted an association between the regressive type and a lower
frequency of WTX (AMER1, Xq) loss. Most aberrations, including
1q gain, were somewhat less common in stage I than in higher stage
tumors (Data Supplement Table S4).
Univariable Outcome Analysis of 1q Gain
In the complete series of 586 patients (Table 1; Figs 2A and 2B),
167 tumors (28.5%) had 1q gain. Five-year EFS in the 1q-gain group
was 75.0% (95% CI, 68.5% to 82.0%) and 88.2% in the no-gain
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group (95% CI, 85.0% to 91.4%). The corresponding OS values
were 88.4% (95% CI, 83.5% to 93.6%) and 94.4% (95% CI,
92.1% to 96.7%), respectively. At the alpha signiﬁcance level of
.05, univariable analyses using the Cox proportional hazards
regression model showed that 1q gain was associated with
poorer EFS (hazard ratio [HR], 2.33; log-rank P, .001) and OS
(HR, 2.16; P = .01).
Because 1q gain as a potential biomarker would be of most
value in optimizing risk stratiﬁcation in localized tumors, we
also considered two important subsets. The ﬁrst consisted of 441
patients with localized disease (stage I to III), intermediate-risk
histology tumors according to the SIOP classiﬁcation. In uni-
variable analysis (Table 1; Figs 2C and 2D), 1q gain was sig-
niﬁcantly associated with inferior EFS (P = .004; HR, 2.21)
but not OS (P = .99; HR, 1.01). The second subset was selected to
allow direct comparison with the Children’s Oncology Group risk
stratiﬁcation. Among 482 patients with localized, nonanaplastic
tumors (ie, excluding both diffuse and focal anaplastic but including
blastemal-type WTs), 1q gain was associated with poorer EFS
(P = .001; HR, 2.34) but not OS (P = .1; HR, 2.48; Table 1; Figs 2E
and 2F).
Univariable Outcome Analysis of 1p Loss and 16q Loss
Neither 1p loss nor 16q loss, nor combined loss of 1p and 16q,
considered as a single biomarker in a univariable Cox model, was
signiﬁcantly associated with EFS or OS in the entire tumor series at
the P = .05 level (Data Supplement). This was also true for the
subsets, with the single exception of amarginal association between
1p loss and poorer OS in nonanaplastic patients (Table 1; Data
Supplement Figs S1, S2, and S3).
Multivariable Outcome Analyses
In a multivariable outcome analysis including 1q gain, 1p loss,
16q loss, tumor stage and histologic risk group, sex, and age, 1q
gain was signiﬁcantly associated with poorer EFS (HR, 1.98;
P = .002), but not OS (HR, 1.61; P = .16; Table 2). The only other
independent factors of those assessed for adverse outcome in the
full series (N = 586) were high-risk histology and stage IV disease.
The signiﬁcant independent association of 1q gain with adverse
EFS but not OS persisted in the subsets of intermediate-risk his-
tology, localized WT (n = 440; EFS HR, 1.92; P = .04) and non-
anaplastic, localized WT (n = 481; EFS HR, 2.0; P = .02).
Univariable Analysis of Gene-Specific Markers
The outcome data for the other markers covered by the assay
were also analyzed on an exploratory basis (Table 1; Data Sup-
plement Figs S4-S9). MYCN (2p) gain was signiﬁcantly associated
with poorer EFS and OS in the complete data set, in the localized
disease intermediate-risk subset, and in the localized disease subset
with anaplastic WTs excluded (Data Supplement Fig S4). Using
a more speciﬁc deﬁnition of MYCN gain, MYCN-only gain (ex-
cluding from the MYCN-gain group those tumors in which the
DYSF control probe on 2pwas also gained, because gains at both loci
were likely to be whole-arm gains), we saw higher HRs and lower
P values (Table 1; Data Supplement Fig S5). Similarly, TP53 (17p) loss
was signiﬁcantly associated with inferior EFS and OS in the complete
series and, perhaps surprisingly, in both subsets, neither of which
included diffuse anaplastic WTs (Table 1; Data Supplement Fig S6).
A third copy number change, loss of the FBXW7 locus on
4q, was signiﬁcantly associated with poorer EFS and OS in the
complete 586 tumor series, but only with poorer EFS in both
Table 2. Multivariable Survival Analyses
Patient Series Variable Comparison
Event-Free Survival Overall Survival
P HR Lower Upper P HR Lower Upper
Unselected patients (n = 585) 1p loss No loss .95 0.98 0.5 1.91 .45 0.67 0.24 1.89
1q gain No gain .002 1.98 1.27 3.07 .16 1.61 0.83 3.15
16q loss No loss .63 1.14 0.68 1.91 .39 1.37 0.67 2.83
Female Male .98 0.99 0.65 1.51 .81 0.93 0.49 1.74
Stage II Stage I .43 1.27 0.71 2.27 .06 3.13 0.96 10.26
Stage III Stage I .17 1.52 0.83 2.79 .01 4.39 1.36 14.12
Stage IV Stage I , .001 4.58 2.58 8.15 , .001 21.65 6.93 67.66
High risk Intermediate risk .001 2.28 1.41 3.68 , .001 8.13 4.05 16.32
Age Per unit .06 1.01 1 1.01 .48 1 0.99 1.01
IR stage I-III (n = 440) 1p loss No loss .97 1.02 0.41 2.5 .84 0.81 0.1 6.74
1q gain No gain .04 1.92 1.05 3.51 .44 0.56 0.13 2.42
16q loss No loss .64 1.2 0.56 2.55 .09 3.51 0.82 15.12
Female Male .27 0.73 0.41 1.28 .04 0.24 0.06 0.92
Stage II Stage I .76 1.11 0.57 2.18 .13 3.25 0.71 14.82
Stage III Stage I .13 1.73 0.85 3.54 .02 7.01 1.45 33.78
Age Per unit .32 1 1 1.01 .71 1 0.99 1.02
Non-AH stage I-III (n = 481) 1p loss No loss .73 1.15 0.52 2.54 .45 1.75 0.4 7.61
1q gain No gain .02 2 1.13 3.57 .62 1.39 0.38 5.11
16q loss No loss .96 0.98 0.46 2.06 .77 1.27 0.26 6.29
Female Male .33 0.77 0.45 1.31 .04 0.24 0.06 0.93
Stage II Stage I .36 1.34 0.72 2.5 .05 5.12 0.99 26.4
Stage III Stage I .26 1.51 0.74 3.08 .06 5.58 0.91 34.08
High risk Intermediate risk .71 0.85 0.38 1.94 .45 1.71 0.42 7
Age Per unit .11 1.01 1 1.01 .53 1.01 0.99 1.02
Abbreviations: AH, anaplastic histology; HR, hazard ratio; IR, intermediate risk.
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Fig 2. (A, C, E) Event-free (EFS) and (B, D, F) overall survival (OS) curves for (A, B) complete series, (C, D) intermediate-risk localized disease, and (E, F) nonanaplastic
localized disease Wilms tumors, stratiﬁed by 1q status. AH, anaplastic histology.
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subsets (Table 1; Data Supplement Fig S7). No signiﬁcant
associations were noted between the copy number status of
WT1 and outcome at the P = .05 signiﬁcance level (Table 1;
Data Supplement Fig S8). For WTX, there was no signiﬁcant
association with EFS, but improved OS was marginally asso-
ciated with copy number loss in the complete series only (P = .04;
Data Supplement Fig S9).
DISCUSSION
This is, to our knowledge, the ﬁrst study to carry out a large-scale
analysis of 1q copy number aberrations in WT sampled at ne-
phrectomy after neoadjuvant chemotherapy according to the
SIOPWT 2001 protocol. The clinical characteristics of the patient
cohort were representative of the entire registered population
who had received preoperative chemotherapy and presented with
unilateral disease; 586 patients with stage I to IVWT, including all
intermediate- and high-risk histologic subtypes, were analyzed.
We found that 1q gain is signiﬁcantly associated with poorer EFS
and OS in univariable analyses, with HRs in excess of two-fold for
relapse and death. These results are broadly consistent with those
recently reported in a study of patients treated by immediate
nephrectomy under Children’s Oncology Group protocols with-
out preoperative chemotherapy26 and, although it is essential to
assess 1q gain independently in cohorts treated under both regi-
mens, it is encouraging to note that it seems to be a prognostically
valuable marker regardless of treatment protocol. However, in
our multivariable analysis of the SIOP data, which also con-
sidered 1p loss, 16q loss, sex, stage, age, and histologic risk
group, 1q gain remained signiﬁcantly associated only with EFS
(HR, 1.98; P = .002) and not OS (HR, 1.61; P = .16). This lack of
association with OS is perhaps not surprising, given the com-
paratively low number of deaths in the patient series (41,
compared with 92 relapses), reﬂecting the relative success of
second-line therapy.
Because just over half of all relapses occur in children with
localized WT that are not of high-risk histology, we analyzed this
subset of patients (n = 441) in which treatment intensiﬁcation to
reduce relapse risk would be clinically appropriate and feasible.
Here, we found that 1q gain retained its independent prognostic
signiﬁcance for EFS (HR, 1.92; P = .04) but not OS in multivariable
analysis. Similar results (HR, 2.00; P = .02) were obtained for
localized nonanaplastic tumors (n = 481), excluding both diffuse
and focal anaplastic WTs but retaining blastemal type. This subset
is comparable to the current North American deﬁnition of fa-
vorable histology for localized patients treated by immediate ne-
phrectomy (where blastemal type, which implies chemoresistance,
cannot be deﬁned).
In contrast to a previous report on immediate nephrectomy
patients,20 we did not ﬁnd that the combination of 1p loss and 16q
loss was prognostically signiﬁcant in the SIOP series in the uni-
variable or multivariable analyses. This was true for both EFS and
OS, in the entire series, and in the nonanaplastic and intermediate-
risk subsets. However, the size of our sample series (signiﬁcantly
smaller than the immediate nephrectomy cohort) meant that the
current study did not have sufﬁcient power to assess reliably the
prognostic signiﬁcance of relatively rare aberrations such as
combined 1p and 16q loss, observed in only 16 patients (three of
whom relapsed). We note also that any copy neutral loss of het-
erozygosity, another possible mechanism of allele loss at these loci,
would not be detected by MLPA. A substantially larger series would
be required to obtain deﬁnitive results for this rare combined
marker in SIOP patients.
In a previous study,18 we presented an analysis ofMYCN copy
number status that included 234 of the samples described in this
study. Therefore, our observations are not independent, but the
current expanded series should give a more reliable indication of
the prognostic relevance of MYCN gain. As before, we note that
MYCN gain seems to be a promising adverse prognostic indicator
for WT, for both EFS and OS (Data Supplement Fig S4). We also
analyzed the data using a more speciﬁc deﬁnition of gain (MYCN-
only gain; Data Supplement Fig S5), excluding whole-arm gains.
The adverse association with both EFS and OS was retained in all
univariable analyses, but with lower P values and higher HRs
throughout, perhaps suggesting that the type of genomic dis-
ruption that has given rise to MYCN gain, rather than the relative
dose of MYCN with regard to the genomic baseline, is more
prognostically relevant. A higher resolution (eg, single nucleotide
polymorphism array) platform that allows precise delineation of
the region of gain and distinguishes between focal events, such as
those we described previously,13 and larger segmental changes
would allow us to address this question.
In a previous study we described an association between poor
outcome and TP53 aberrations (typically point mutation co-
incident with whole-arm copy number loss of 17p) in diffuse
anaplastic tumors.21 Interestingly, TP53 (17p) loss in the current
study was associated with poorer EFS and OS, even in the subsets
that excluded anaplastic tumors. It is currently not known whether
the nonanaplastic tumors with copy number loss at this locus also
had TP53 mutations or whether these tumors had any unusual
histologic features, such as nuclear unrest.31
Loss of the FBXW7 locus on 4q was signiﬁcantly associated
with poorer EFS and OS in the complete tumor series and with
adverse EFS only in the subsets. In earlier studies, we reported
focal homozygous loss and point mutation of FBXW7 in several
intermediate-risk histology WTs,13 as well as broader but typically
single copy loss of 4q associated with anaplasia30; the current assay
does not distinguish between these types of aberrations.
Optimizing treatment to minimize the risk of long-term
adverse effects without compromising EFS or OS is a principal
aim of clinical research in WT. The previous SIOP randomized
trial5,6 showed that therapeutic intensity could be reduced in
patients with localized intermediate-risk tumors without affecting
OS, at the cost of a 4.4% reduction in EFS (95% CI, 0.4% to 9.3%).
Because it is clearly desirable for patients to avoid even treatable
relapses, further reﬁnement of ﬁrst-line therapy remains a priority,
and novel biomarkers may provide the key data required to im-
prove risk stratiﬁcation and maximize EFS. In this study, we have
shown that MLPA provides a rapid and effective means of de-
termining the status of copy number aberrations associated with
poorer EFS. The relatively high frequency of 1q gain makes this
marker particularly attractive for potential use in risk stratiﬁcation.
However, any change in intensity on the basis of 1q status alone
would affect a signiﬁcant proportion of patients who have expe-
rienced a reasonably good EFS when treated with current therapies
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and where relapse is salvageable. Hence, the SIOP Renal Tumours
Study Group considers it may be more appropriate to deﬁne risk
groups for treatment stratiﬁcation on the basis of several combined
molecular biomarkers, taking account of our ﬁndings of the
adverse signiﬁcance of MYCN gain and TP53 loss and in-
corporating mutations in recently discovered WT genes, some
of which are reported to have prognostic signiﬁcance. This
requires a prospective clinical study powered to include tumor
stage and histologic risk group, both individually signiﬁcant in
our multivariable analysis, alongside quantitative assessment
of the volume of blastema that survives preoperative chemo-
therapy, a further potential prognostic factor.32 This prospective
study will also incorporate multiple sampling of each WT to
determine the extent of intratumoral heterogeneity of 1q gain
and other biomarkers. It will register all patients with a newly
diagnosed renal tumor and continue the risk stratiﬁcation and
treatment arms for localized WTused in the SIOPWT 2001 trial.
The study will be known as UMBRELLA, and is expected to open
in 2016.
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